A5083770629- Thyroid Cancer Diagnosis and Treatment
- Thyroid Disorders and Treatments
- Thyroid and Parathyroid Surgery
- Neuroendocrine Tumor Research Advances
- Head and Neck Anomalies
- Cancer-related Molecular Pathways
- BRCA gene mutations in cancer
- Radiation Dose and Imaging
- Genetic factors in colorectal cancer
- Pituitary Gland Disorders and Treatments
- Growth Hormone and Insulin-like Growth Factors
- S100 Proteins and Annexins
- Radiopharmaceutical Chemistry and Applications
- Nutrition, Genetics, and Disease
- Effects of Radiation Exposure
- Telomeres, Telomerase, and Senescence
- Radiomics and Machine Learning in Medical Imaging
- Monoclonal and Polyclonal Antibodies Research
- Bone health and treatments
- Medical and Biological Sciences
- T-cell and B-cell Immunology
- Cell death mechanisms and regulation
- Salivary Gland Tumors Diagnosis and Treatment
- Renal cell carcinoma treatment
- Medical Imaging and Pathology Studies
University of Siena
2014-2023
Humanitas University
2019-2020
Istituti di Ricovero e Cura a Carattere Scientifico
2020
Ospedale Santa Maria alle Scotte
2008-2019
Azienda Ospedaliera Universitaria Senese
2012-2015
Universidade Federal do Rio de Janeiro
2011
Rigshospitalet
2011
Copenhagen University Hospital
2011
Dana-Farber Cancer Institute
2009
Institut Gustave Roussy
2009
Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Since the publication of American Association's guidelines for management these disorders was published in 2006, large amount new information has become available, prompting revision guidelines.Relevant articles through December 2008 were reviewed by task force categorized topic level evidence according to modified schema used United States Preventative Services Task Force.The...
Journal Article European consensus for the management of patients with differentiated thyroid carcinoma follicular epithelium Get access Furio Pacini, Pacini Section Endocrinology and Metabolism, University Siena, Via Bracci, 53100 Italy (Correspondence should be addressed to F Pacini; Email: pacini8@unisi.it) Search other works by this author on: Oxford Academic Google Scholar Martin Schlumberger, Schlumberger Service de Médicine Nucléaire, Institut Gustave Roussy, Villejuif, France Henning...
Recombinant human TSH has been developed to facilitate monitoring for thyroid carcinoma recurrence or persistence without the attendant morbidity of hypothyroidism seen after hormone withdrawal. The objectives this study were compare effect administered recombinant with withdrawal on results radioiodine whole body scanning (WBS) and serum thyroglobulin (Tg) levels. Two hundred twenty-nine adult patients differentiated cancer requiring WBS studied. Radioiodine Tg measurements performed...
The survival rate of patients with medullary thyroid carcinoma (MTC) is significantly better in diagnosed and treated when the tumor limited to thyroid. In a pioneer study carried out 1991, we demonstrated that routine measurement serum calcitonin (CT) nodular disease allowed preoperative diagnosis unsuspected sporadic MTC accuracy than fine needle aspiration cytology (FNAC). This finding has been confirmed subsequent studies. present report results CT screening 10,864 seen years 1991–1998...
Medullary thyroid carcinoma (MTC) is a well-differentiated tumor that maintains the typical features of C cells. An advanced stage and presence lymph node metastases at diagnosis have been demonstrated to be most important bad prognostic factors. Somatic RET mutations found in 40-50% MTCs. Although relationship between somatic prognosis has described, data are controversial performed small series with short-term follow ups. The aim this study was verify value large MTCs long up.We studied...
After surgery for differentiated thyroid carcinoma, many patients are treated with radioiodine to ablate remnant tissue. This procedure has been performed the patient in hypothyroid state promote endogenous TSH stimulation and is often associated symptoms impaired quality of life. OBJECTIVE AND INTERVENTION: international, randomized, controlled, multicenter trial aimed compare efficacy safety recombinant human (rhTSH) prepare euthyroid on L-thyroxine therapy (euthyroid group) tissue 3.7 GBq...
Recombinant human TSH (rhTSH)-stimulated thyroglobulin (Tg) measurement and 131I whole body scan (WBS) have been validated as informative tests in the postsurgical follow-up of differentiated thyroid carcinoma. We report diagnostic accuracy Tg WBS, alone or combination, after rhTSH stimulation a retrospective, consecutive series patients undergoing for cancer. Routine procedures also include neck ultrasound every patient post-therapy WBS when indicated. studied 340 with carcinoma, previously...
Purpose This phase II study investigated the efficacy and tolerability of motesanib, an investigational, highly selective inhibitor vascular endothelial growth factor receptors 1, 2, 3; platelet-derived receptor; Kit in advanced medullary thyroid cancer (MTC). Patients Methods with locally or metastatic, progressive symptomatic MTC received motesanib 125 mg/d orally for up to 48 weeks until unacceptable toxicity disease progression. The primary end point was objective response by independent...
Context: Fine-needle aspiration cytology (FNAC) is the gold standard for differential diagnosis of thyroid nodules but has limitation inadequate sampling or indeterminate lesions. Objective: We aimed to verify whether search cancer-associated protooncogene mutations in cytological samples may improve diagnostic accuracy FNAC. Study Design: One hundred seventy-four consecutive patients undergoing surgery were submitted FNAC (on 235 nodules) that was used and molecular analysis BRAF, RAS, RET,...
After initial treatment, differentiated thyroid cancer (DTC) patients are stratified as low and high risk based on clinical/pathological features. Recently, a stratification additional clinical data accumulated during follow-up has been proposed.To evaluate the predictive value of delayed (DRS) obtained at time first diagnostic control (8-12 months after treatment).We reviewed 512 with DTC whose assessment was initially defined according to American (ATA) European Thyroid Association (ETA)...
Abstract Purpose: Positive results of phase I studies evaluating lenvatinib in solid tumors, including thyroid cancer, prompted a II trial advanced medullary carcinoma (MTC). Experimental Design: Fifty-nine patients with unresectable progressive MTC per Response Evaluation Criteria In Solid Tumors (RECIST) v1.0 within the prior 12 months received (24-mg daily, 28-day cycles) until disease progression, unmanageable toxicity, withdrawal, or death. Prior anti-VEGFR therapy was permitted. The...